1 |
Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566
DOI
ScienceOn
|
2 |
Vanhaesebroeck B, Alessi DR: The P13K-PDK1 connection: more than just a road to PKB. Biochem J. 2000;346:561-576
DOI
ScienceOn
|
3 |
Stephens LR, Jackson TR, Hawkins PT: Agonist-stimulated synthesis of phosphatidylinositol (3,4,5)-triphosphate: a new intracellular signalling system? Biochim Biophys Acta. 1993;1179: 27-75
DOI
ScienceOn
|
4 |
Cheng JQ, Ruggeri B, Klein WM, et al: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996; 93:3636-3641
|
5 |
Basu S, Totty NF, Irwin MS, Sudol M, Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003;11:11-23
|
6 |
Wendel HG, De Stanchina E, Fridman JS, et al: Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature. 2004;428:332-337
DOI
ScienceOn
|
7 |
Sawyers CL: Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-1340
DOI
ScienceOn
|
8 |
Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001;411:355-365
DOI
ScienceOn
|
9 |
Amomphimoltham P, Sriuranpong V, Patel V, et al: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res. 2004; 10:4029-4037
DOI
ScienceOn
|
10 |
Roskoski R Jr: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 2003;309:709-717
DOI
PUBMED
ScienceOn
|
11 |
Hibi K, Takahashi T, Sekido Y, et al: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291-2296
PUBMED
|
12 |
Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib ), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1 :493-502
DOI
ScienceOn
|
13 |
Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer; 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27
DOI
PUBMED
ScienceOn
|
14 |
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932
|
15 |
Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Rev Cancer. 2002;2:489-501
DOI
ScienceOn
|
16 |
McCormick F: Cancer: survival pathways meet their end. Nature. 2004;428:267-269
DOI
PUBMED
ScienceOn
|
17 |
Grille SJ, Bellacosa A, Upson J, et al: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63:2172-2178
|
18 |
Ballacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280-285
DOI
ScienceOn
|
19 |
Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580
DOI
PUBMED
ScienceOn
|
20 |
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000; 100:57-70
DOI
ScienceOn
|